Albizia julibrissin DURAZZ. from wild collection – a multivariate data analysis approach

The aim of our research is to investigate traditional herbal medicines to discover new, plant-based alternatives for the treatment of chronic inflammatory diseases. [1] The bark of Albizia julibrissin Durazz., the most valuable candidate emerging from the screening phase, was collected under the guidance of local botanists, in Hubei Province, China, from 9 different locations and 14 different trees. Extraction was performed by successive ultra-sonication of the powdered bark with dichloromethane and methanol, followed by liquid-liquid fractionation of the extracts with dichloromethane, ethyl-acetate, n-butanol and water. LPS- and IFNγ- induced RAW 264.7 macrophages and BV2 microglia cells were used to determine the anti-inflammatory effect of the bark extracts via detection of NO with Griess-reagent, while XTT assay was used to determine respective cytotoxicity. [2] Metabolite profiles were analyzed by means of UHPLC-HRMS analysis. Phytochemical profiles and pharmacological data have been correlated by orthogonal projection to latent structures discriminant analysis (OPLS-DA) to deduce potentially active candidate compounds. Identification of candidate compounds by UHPLC-HRMS dereplication and isolation is in progress.

Publication History

Article published online:
13 December 2021

• References

• 1 Waltenberger, B. et al. 2016. Monatshefte für Chemie – Chemical Monthly, 147(3), pp. 479–491. doi:10.1007/s00706-015-1653-y
• 2 Tran, H.T. et al. 2019. Phytomedicine, 62, p. 152951. doi:10.1016/j.phymed.2019.152951